INFLUX Influx Healthtech Q2 FY26 results (Jul–Sep 2025) and concall
Influx Healthtech reported strong H1 FY26 results with significant revenue and profit growth, driven by capacity expansions and diversification efforts across nutraceuticals, cosmetics, and ayurveda. The company is strategically investing IPO proceeds in new facilities and innovative product lines like nutritional beverages, while also expanding its global regulatory footprint. Management acknowledges minor delays in new facility commissioning due to weather and is addressing working capital efficiency.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q4 FY25 | Q2 FY26 |
|---|---|---|---|
| Revenue | 48 | 57 | 67 |
| EBITDA | 9 | 11 | 15 |
| Net profit | 6 | 8 | 10 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
